The results of this prospective study support previous findings regarding the influence of SNPs on angiogenic VEGF genes, and the circulating levels of VEGF on the clinical outcomes of patients with non-squamous NSCLC receiving antiangiogenic treatment such as bevacizumab. The gene discussed is VEGFA; the disease is non-small cell lung carcinoma.